LACTOVET 24 ML

1. NAME OF THE VETERINARY MEDICINAL PRODUCT
LACTOVET
50 µg/ml, oral solution for dogs
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

3. PHARMACEUTICAL FORM

Oral solution
4. CLINICAL DATA
4.1. target species
Perras
4.2. Indications for use, specifying the target species
LACTOVET is used for the treatment of pseudopregnancy in bitches and to suppress the
lactation in bitches, in the following situations:
– Separation of the pups immediately after delivery.
– Early weaning.
– Fetal death and/or abortion at the end of pregnancy.
– Lactation after ovariohysterectomy.
All of these are circumstances that can give rise to undesirable consequences, such as
such as breast engorgement and mastitis if a treatment is not administered to inhibit the
lactation.
4.3. contraindications
They have not been described
4.4. Special warnings for each target species
They have not been described.
4.5. Special precautions for use
Special precautions for use in animals
After each administration, dry the dropper and place it back in its case.
Special.

Special precautions to be taken by the person administering the medicinal product to
animals
They have not been described.
4.6. Adverse reactions (frequency and seriousness)
The only possible side effects are drowsiness, anorexia, and vomiting. They are rare,
transitory and moderate. Vomiting can usually occur only after the
first administration. In this case, treatment should not be interrupted as this symptom
it will not be presented with the next administrations.
4.7. Use during pregnancy, lactation or lay
Do not administer to pregnant females.
4.8. Interaction with other medicinal products and other forms of interaction
They have not been described
4.9. Dosage and route of administration
LACTOVET is so far intended only for bitches. LACTOVET should be administered
orally directly into the animal's mouth or mixed with the feed at the following
dose :
0,1 ml/kg bw (5 mcg cabergoline/kg) once daily for 4-6 consecutive days, depending on
the severity of the clinical picture.
For small breeds or for animals weighing less than 5 kg, it is recommended
administer the dose in drops: 0,1 ml of solution equivalent to 3 drops.
In case of relapse, animals can be treated again according to the indicated dose.
previously.
4.10. Overdose (symptoms, emergency procedures, antidotes)
In case of overdose, vomiting may occur. This effect can be antagonized
with parenteral administration of an antidopaminergic agent such as metoclopramide.
•
4.11. Waiting time
Not applicable.
5. PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group: Prolactin inhibitors, ATCvet code QG02CB03.
Cabergoline (new ergoline derivative) has a hypoprolactinemia effect.

Cabergoline inhibits prolactin secretion in rats under different conditions
experimental. The peak of prolactin inhibition, after a single oral dose, is
it reaches 4-8 hours and persists for several days, depending on the dose administered.
The hypoprolactinemia effect of cabergoline lasts longer than that of the others.
ergoline derivatives.
Cabergoline also inhibits lactation, which is a prolactin-dependent process.
When administered orally to lactating rats, rabbits and bitches for 4 days
established after farrowing, significantly reduces the body weight of the litter, with
an ED50 (the dose that reduces weight gain in newborns by 50%) of 29, 15,0, and
1,50 mcg/kg/day, respectively.
Cabergoline acts directly on the anterior pituitary, stimulating receptors
dopamine inhibitors. Its long-lasting hypoprolactinemia effect can be attributed to the
at least in part, to the persistence of the compound in the pituitary gland.
Cabergoline has no other effects on the endocrine system and has central effects.
little or none.
In anesthetized dogs, it produces a slight decrease in blood pressure without affecting the
heart rate.
Like the other ergoline derivatives, cabergoline can induce emesis in the
dogs, but in an experimental study the ED50 for emesis was about 15 times
greater than ED50 to inhibit lactation in bitches.
6. PHARMACEUTICAL DATA
6.1. List of excipients
medium chain triglycerides
6.2. incompatibilities
They have not been described.
6.3. Period of validity
Shelf life of the veterinary medicinal product packaged for sale: 3 years.
Shelf-life after first opening the immediate packaging: 12 days
6.4. Special storage precautions
LACTOVET must be stored at a temperature below 25 ºC.
6.5. Nature and composition of the immediate packaging
Amber glass bottles, type III.

Pilfer-Proof aluminum caps with a gasket, food grade, low polyethylene
density.
Dropper: colorless glass tube, type III, food grade PVC nipple, plastic wrap
polypropylene sheet.
Syringe: clear polypropylene tube, high-density polyethylene plunger
transparent fitted with a black ring (sealing joint) of inert silicone.
Formats:
3 ml bottle + 0,7 ml dropper
7 ml bottle + 1 ml dropper
15 ml bottle + 1 ml dropper
Bottle with 24 ml + 3 ml syringe
Not all formats may be marketed.
6.6. Special precautions for disposal of the veterinary medicinal product
used or, where appropriate, the residues derived from its use
They have not been described.
7. MARKETING AUTHORIZATION HOLDER
CEVA ANIMAL HEALTH
C/ Caravel La Niña, 12
BARCELONA 08017
8. MARKETING AUTHORIZATION NUMBER
2071 ESP
9. DATE OF THE FIRST AUTHORIZATION OR RENEWAL OF THE
AUTHORIZATION
30 September 2009
10. DATE OF REVISION OF THE TEXT
November 08th 2010
PROHIBITION OF SALE, DISPENSATION AND/OR USE
Dispensing conditions: Medicine subject to veterinary prescription